DSpace@İnönü

Yazar "Cabuk, D." için listeleme

Yazar "Cabuk, D." için listeleme

Sırala: Sıra: Sonuçlar:

  • Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naïve breast cancer: real-life practice outcomes 
    Esin, E.; Oksuzoglu, B.; Bilici, A.; Cicin, I.; Kostek, O.; Kaplan, M.A.; Aksoy, S.; Aktas, B.Y.; Ozdemir, O.; Alacacioglu, A.; Cabuk, D.; Sumbul, A.T.; Sakin, A.; Paydas, S.; Yetisir, E.; Er, O.; Korkmaz, T.; Yildirim, N.; Sakalar, T.; Demir, H.; Artac, M.; Karaagac, M.; Harputluoglu, H.; Bilen, E.; Erdur, E.; Degirmencioglu, S.; Aliyev, A.; Cil, T.; Olgun, P.; Basaran, G.; Gumusay, O.; Demir, A.; Tanrikulu, E.; Yumuk, P.F.; Imamoglu, I.; Oyan, B.; Cetin, B.; Haksoyler, V.; Karadurmus, N.; Erturk, I.; Evrensel, T.; Yilmaz, H.; Beypinar, I.; Kocer, M.; Pilanci, K.N.; Seker, M.; Urun, Y.; Eren, T.; Demirci, U.; Uluc Oyan, B.; Beypinar; Kocer; Turkish Oncology Group (2019)
    Purpose: In this study, we aimed to describe the real-life practice outcomes of pertuzumab–trastuzumab–taxane (PTT) combination in visceral organ metastatic, trastuzumab-naive breast cancer (BC) patients. Methods: This ...
  • The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early-stage human epidermal growth factor receptor 2-positive breast cancer: Turkish Oncology Group study 
    Özdemir, Ö.; Zengel, B.; Yildiz, Y.; Uluç, B.O.; Cabuk, D.; Ozden, E.; Salim, D.K.; Paydas, S.; Demir, A.; Diker, O.; Pilanci, K.N.; Sönmez, Ö.U.; Vatansever, S.; Dogan, I.; Gulmez, A.; Cakar, B.; Gursoy, P.; Yildirim, M.E.; Ayhan, M.; Karadurmus, N.; Aykan, M.B.; Cevik, G.T.; Sakalar, T.; Hacibekiroglu, I.; Gülbagci, B.B.; Dincer, M.; Garbioglu, D.B.; Kemal, Y.; Nayir, E.; Taskaynatan, H.; Yilmaz, M.; Avci, O.; Sari, M.; Coban, E.; Atci, M.M.; Esen, S.A.; Telli, T.A.; Karatas, F.; Inal, A.; Demir, H.; Kalkan, N.O.; Yilmaz, C.; Tasli, F.; Alacacioglu, A. (2022)
    In our study, we aimed to evaluate the pathological response rates and side effect profile of adding pertuzumab to the treatment of HER2+ locally advanced, inflammatory, or early-stage breast cancer. This study was conducted ...